Fibulin-2: A Novel Biomarker for Differentiating Grade II from Grade I Meningiomas



Sofela, Agbolahan A, Hilton, David A, Ammoun, Sylwia, Baiz, Daniele, Adams, Claire L, Ercolano, Emanuela, Jenkinson, Michael D ORCID: 0000-0003-4587-2139, Kurian, Kathreena M, Teo, Mario, Whitfield, Peter C
et al (show 2 more authors) (2021) Fibulin-2: A Novel Biomarker for Differentiating Grade II from Grade I Meningiomas. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 22 (2). E560-.

Access the full-text of this item by clicking on the Open Access link.

Abstract

There is an unmet need for the identification of biomarkers to aid in the diagnosis, clinical management, prognosis and follow-up of meningiomas. There is currently no consensus on the optimum management of WHO grade II meningiomas. In this study, we identified the calcium binding extracellular matrix glycoprotein, Fibulin-2, via mass-spectrometry-based proteomics, assessed its expression in grade I and II meningiomas and explored its potential as a grade II biomarker. A total of 87 grade I and 91 grade II different meningioma cells, tissue and plasma samples were used for the various experimental techniques employed to assess Fibulin-2 expression. The tumours were reviewed and classified according to the 2016 edition of the Classification of the Tumours of the central nervous system (CNS). Mass spectrometry proteomic analysis identified Fibulin-2 as a differentially expressed protein between grade I and II meningioma cell cultures. Fibulin-2 levels were further evaluated in meningioma cells using Western blotting and Real-time Quantitative Polymerase Chain Reaction (RT-qPCR); in meningioma tissues via immunohistochemistry and RT-qPCR; and in plasma via Enzyme-Linked Immunosorbent Assay (ELISA). Proteomic analyses (<i>p</i> < 0.05), Western blotting (<i>p</i> < 0.05) and RT-qPCR (<i>p</i> < 0.01) confirmed significantly higher Fibulin-2 (FBLN2) expression levels in grade II meningiomas compared to grade I. Fibulin-2 blood plasma levels were also significantly higher in grade II meningioma patients compared to grade I patients. This study suggests that elevated Fibulin-2 might be a novel grade II meningioma biomarker, when differentiating them from the grade I tumours. The trend of Fibulin-2 expression observed in plasma may serve as a useful non-invasive biomarker.

Item Type: Article
Uncontrolled Keywords: meningioma, atypical, benign, biomarker, plasma
Divisions: Faculty of Health and Life Sciences
Faculty of Health and Life Sciences > Institute of Systems, Molecular and Integrative Biology
Depositing User: Symplectic Admin
Date Deposited: 08 Jul 2021 09:15
Last Modified: 25 Jan 2024 19:22
DOI: 10.3390/ijms22020560
Open Access URL: https://doi.org/10.3390/ijms22020560
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3129271